PT3250563T - Triazois substituídos e métodos relacionados aos mesmos - Google Patents
Triazois substituídos e métodos relacionados aos mesmosInfo
- Publication number
- PT3250563T PT3250563T PT167032507T PT16703250T PT3250563T PT 3250563 T PT3250563 T PT 3250563T PT 167032507 T PT167032507 T PT 167032507T PT 16703250 T PT16703250 T PT 16703250T PT 3250563 T PT3250563 T PT 3250563T
- Authority
- PT
- Portugal
- Prior art keywords
- methods relating
- substituted triazoles
- triazoles
- substituted
- relating
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110415P | 2015-01-30 | 2015-01-30 | |
| US201562259314P | 2015-11-24 | 2015-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3250563T true PT3250563T (pt) | 2022-02-09 |
Family
ID=55305123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167032507T PT3250563T (pt) | 2015-01-30 | 2016-01-29 | Triazois substituídos e métodos relacionados aos mesmos |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9718789B2 (OSRAM) |
| EP (1) | EP3250563B1 (OSRAM) |
| JP (1) | JP6728198B2 (OSRAM) |
| KR (1) | KR102575601B1 (OSRAM) |
| CN (1) | CN107406420B (OSRAM) |
| AU (1) | AU2016211292B2 (OSRAM) |
| BR (1) | BR112017016488A2 (OSRAM) |
| CA (1) | CA2975474C (OSRAM) |
| CY (1) | CY1125082T1 (OSRAM) |
| DK (1) | DK3250563T3 (OSRAM) |
| ES (1) | ES2905878T3 (OSRAM) |
| HR (1) | HRP20220327T1 (OSRAM) |
| HU (1) | HUE058156T2 (OSRAM) |
| IL (1) | IL253705B (OSRAM) |
| LT (1) | LT3250563T (OSRAM) |
| MX (1) | MX378932B (OSRAM) |
| PL (1) | PL3250563T3 (OSRAM) |
| PT (1) | PT3250563T (OSRAM) |
| RS (1) | RS62862B1 (OSRAM) |
| RU (1) | RU2718049C2 (OSRAM) |
| SI (1) | SI3250563T1 (OSRAM) |
| WO (1) | WO2016123533A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40281B1 (fr) | 2014-06-03 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
| EP3194374B1 (en) | 2014-09-15 | 2018-08-01 | Idorsia Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
| SI3250563T1 (sl) | 2015-01-30 | 2022-04-29 | Neurocrine Biosciences, Inc. | Substituirani triazoli in z njimi povezani postopki |
| EP3554490B1 (en) | 2016-12-16 | 2022-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
| EP3577099B1 (en) | 2017-02-06 | 2024-01-24 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) * | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| TW513301B (en) * | 1999-03-01 | 2002-12-11 | Novartis Ag | Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders |
| HRP20050053A2 (en) * | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| EP1829867A1 (en) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Imidazole compounds having pharmaceutical activity towards the sigma receptor |
| EP1921073A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| EP1921071A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3- triazole derivatives as sigma receptor inhibitors |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| EP2752411A1 (en) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| SI3250563T1 (sl) | 2015-01-30 | 2022-04-29 | Neurocrine Biosciences, Inc. | Substituirani triazoli in z njimi povezani postopki |
-
2016
- 2016-01-29 SI SI201631489T patent/SI3250563T1/sl unknown
- 2016-01-29 WO PCT/US2016/015740 patent/WO2016123533A1/en not_active Ceased
- 2016-01-29 PT PT167032507T patent/PT3250563T/pt unknown
- 2016-01-29 US US15/010,925 patent/US9718789B2/en active Active
- 2016-01-29 AU AU2016211292A patent/AU2016211292B2/en active Active
- 2016-01-29 KR KR1020177023771A patent/KR102575601B1/ko active Active
- 2016-01-29 CA CA2975474A patent/CA2975474C/en active Active
- 2016-01-29 PL PL16703250T patent/PL3250563T3/pl unknown
- 2016-01-29 JP JP2017540175A patent/JP6728198B2/ja active Active
- 2016-01-29 ES ES16703250T patent/ES2905878T3/es active Active
- 2016-01-29 BR BR112017016488A patent/BR112017016488A2/pt not_active Application Discontinuation
- 2016-01-29 EP EP16703250.7A patent/EP3250563B1/en active Active
- 2016-01-29 HR HRP20220327TT patent/HRP20220327T1/hr unknown
- 2016-01-29 HU HUE16703250A patent/HUE058156T2/hu unknown
- 2016-01-29 DK DK16703250.7T patent/DK3250563T3/da active
- 2016-01-29 LT LTEPPCT/US2016/015740T patent/LT3250563T/lt unknown
- 2016-01-29 RS RS20220093A patent/RS62862B1/sr unknown
- 2016-01-29 CN CN201680016876.2A patent/CN107406420B/zh active Active
- 2016-01-29 MX MX2017009824A patent/MX378932B/es unknown
- 2016-01-29 RU RU2017130474A patent/RU2718049C2/ru active
-
2017
- 2017-06-22 US US15/630,225 patent/US10138214B2/en active Active
- 2017-07-27 IL IL253705A patent/IL253705B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,025 patent/US10738017B2/en active Active
-
2020
- 2020-06-04 US US16/892,718 patent/US11021449B2/en active Active
-
2022
- 2022-03-16 CY CY20221100210T patent/CY1125082T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| IL258931A (en) | Medicinal compounds and methods | |
| LT3215147T (lt) | Neurologinį poveikį mažinantys norketamino junginiai ir būdai | |
| GB2538731B (en) | Methods | |
| PT3250563T (pt) | Triazois substituídos e métodos relacionados aos mesmos | |
| IL247148A0 (en) | Pyrazolone compounds and uses thereof | |
| IL251107A0 (en) | Compounds and methods | |
| GB201518762D0 (en) | Methods | |
| GB201608779D0 (en) | Methods and compounds | |
| GB201503776D0 (en) | Compound and method | |
| GB201508927D0 (en) | Methods | |
| GB201507753D0 (en) | New compounds and uses | |
| GB201504763D0 (en) | Compounds and uses | |
| GB201608776D0 (en) | Methods and compounds | |
| GB201515655D0 (en) | Methods | |
| GB201501593D0 (en) | New compounds and processes | |
| GB201415250D0 (en) | Compound and method | |
| GB201512609D0 (en) | Methods | |
| GB201719043D0 (en) | Methods and compounds | |
| GB201512216D0 (en) | Agents uses and methods | |
| GB201509931D0 (en) | Hyperthermia method | |
| GB201521339D0 (en) | Methods | |
| GB201510756D0 (en) | Methods | |
| GB201509909D0 (en) | Methods | |
| GB201509813D0 (en) | Methods |